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Abstract
Pancreatic cancer (ductal adenocarcinoma) is one of the most lethal malignancies in gastrointestinal system. Till 
now, only margin-negative pancreatectomy is known to be the best treatment option for long-term survival. However, 
the resection rate is reported to be less than 20%. Even in cases of curative resection, most patients generally 
experience disease recurrence and ultimately die of metastatic disease. Therefore, surgery alone is not enough and 
adjuvant systemic chemotherapy should be considered for proper management of pancreatic cancer. But, its related 
toxicity and insufficient oncologic effect requires development of less toxic and more effective alternative treatments 
for pancreatic cancer. Phellinus linteus (PL), a basidiomycete, is a species of mushroom, which is reported to have 
the most potent antitumor effect of the basidiomycetes. Recently, there are accumulating researches discovering 
biologic mechanisms of PL in antitumor effect. However, very few studies were done in pancreatic cancer treatment. 
In this review, literatures demonstrating the anticancer effects of PL were summarized and some encouraging 
research data suggesting mushroom component can be alternative approach even in treating pancreatic cancer 
were reviewed, including our preliminary data suggesting the potential clinical application of PL in treating pancreatic 
cancer.
Keywords: Pancreatic cancer; Phellinus linteus; Basidiomycete; 
Adjuvant chemotherapy
Introduction
Pancreatic cancer (ductal adenocarcinoma) is one of the most 
lethal gastrointestinal malignancies. Complete surgical resection is 
a basic requirement for long-term survival. However, the resection 
rate of pancreatic cancer is only 15-20% because the disease is locally 
advanced or metastatic at initial diagnosis. Even in cases of curative 
resection, most patients experience disease recurrence, especially in 
the liver, and ultimately die of metastatic disease. Gemcitabine has 
been used as standard chemotherapy for pancreatic cancer [1], but, 
most clinical trials that have tested combinations with other cytotoxic 
agents have failed to demonstrate markedly improved oncologic 
outcomes [2]. In spite of high morbidity, FOLFIRINOX is an emerging 
chemotherapeutic agent for metastatic pancreatic cancer treatment 
[3]. However, studies are needed to determine the appropriate dosages 
and clinical applications, such as use in postoperative adjuvant or 
neoadjuvant therapy. Therefore development of less toxic and effective 
alternative treatments for pancreatic cancer is also needed. A potential 
alternative strategy is to investigate and understand the mechanism of 
action of natural medicines with anticancer effects.
Phellinus linteus (PL), a basidiomycete, is a species of mushroom 
whose fruiting body is called sanghuang (Figure 1). This mushroom 
has been widely used in ancient herbal medicines in Korea, China, and 
Japan. In 1968, the antitumor activity of polysaccharides from PL was 
first reported [4]. PL is reported to have the most potent antitumor 
effect of the basidiomycetes [5]. In the last few decades, the use of PL 
for suppressing cancer or enhancing immunity [6] has been actively 
investigated. Biological effects were found to be associated with isolated 
polysaccharides, proteoglycans and other organic compounds. Isolated 
compounds and complex extracts from PL inhibit signal pathways in 
various cancer cells. However, few clinical studies to date have tested 
the oncologic effects of PL, and only a few cases have demonstrated the 
therapeutic effect of PL on primary liver cancer. In Japan, a patient with 
hepatocellular carcinoma and multiple lung metastases was reported to 
experience complete tumor regression 6 months after treatment with 
PL extract [7]. Radiation therapy in combination with PL ingestion 
resulted in spontaneous remission of hepatocellular carcinoma with 
skull metastasis in a Korean patient [8]. 
In this review, we summarize several studies that show the 
anticancer effects of PL. We also provide our preliminary data that 
suggests the potential clinical application of PL in treating pancreatic 
cancer.
Figure 1: General appearance of Phellinus linteus.
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Anticancer effects of Phellinus linteus
The biologically active compoundsin PL are reported to be 
polysaccharides [9], acidic proteoglycans with mixed α- and β-linkages, 
and a (1→6)-branched type (1→3)-glycan [10]. In 1969, Chihara et al. 
[11] demonstrated that polysaccharide extracts from the basidiomycete 
fungus PL suppressed tumor growth in vivo. Recently, new furopyranone 
compounds, phellifuropyranone A and meshimakobnol A/B, isolated 
from fruiting bodies of wild PL, demonstrated antiproliferative 
activity against mouse melanoma and human lung cancer cells in vitro 
[12]. However, the molecular mechanisms responsible for the direct 
antitumor activity have not been fully investigated. 
Protein-bound polysaccharides isolated from PL suppressed the 
proliferation and colony formation of colon cancer cells (SW480). 
This effect was found to be mediated by cell cycle arrest at G2/M phase 
and associated with down regulation of cyclin B1 [13]. Isolated low 
molecular weight compounds from PL such as hispolon demonstrated a 
dose-dependent inhibition of human epidermoid KB cell proliferation 
[14]. Several recent studies demonstrated potential mechanisms of the 
direct anticancer effects of PL extracts on tumor proliferation, growth 
and invasiveness (Table 1).
Immunomodulation
Polysaccharides and proteoglycans extracted from PL might 
stimulate the proliferation of T lymphocytes and the humoral immune 
function, resulting in a secretory and cellular macrophage response. 
Nonspecific immune functions mediated by natural killer cells and 
macrophages increased in vivo and in vitro with treatment with PL. 
PL stimulated humoral immune functions such as T-dependent and 
-independent primary antibody responses, and acted as a polyclonal 
activator of B cells. PL exhibited a wider range of immunostimulation 
and antitumor activity than other polysaccharides isolated from other 
basidiomycetes [15]. 
Kim et al. [16] demonstrated that a novel polysaccharide-protein 
complex extracted from PL markedly increased B-cell proliferation, 
production of cytokines and nitric oxide from macrophages, and NK 
cell-mediated killing of YAC-1 lymphoma cells in vitro. These results 
suggest that PL is a biological response modifier. In vivo, when HT-
29 colon cancer cell-bearing mice were treated with proteoglycans 
extracted from PL, a relative increase in spleen and thymus weights were 
noted. Significant changes in plasma biochemical parameters showed 
that PL acted as an immunopotentiator partly through protecting T 
cells and enhancing mucosal IgA responses [17]. In human hepatoma 
(Hep3B) cell-transplanted mice, an extract of a mycelial culture from 
PL induced significant reduction of tumor size and increased T cell 
numbers, and increased IL-2, IFN-γ, and TNF-α secretion and NK cell 
activity and phagocytic ability [18,19]. NK cells are especially known 
for their ability to lyse a variety of tumor cells by exocytosis of perforin-
containing granules, subsequently forming lytic pores by perforin on 
the target cell membrane. In addition, NK cells are responsible for 
early inhibitory effects on tumor growth and for long-term tumor-
suppressive effects [20,21].The importance of innate immunity in 
pancreatic cancer was recently reiterated by the strong correlation 
between the absolute numbers of NK cells circulating in patients before 
chemotherapy and survival and progression-free interval. The average 
percentage of NK cells before therapy positively correlated with NK 
cytotoxic lytic units, suggesting that cytotoxic functions of NK cells 
are important in pancreatic cancer [22].This suggests that PL-induced 
immunomodulation, especially regarding NK cell activity, needs to be 
further evaluated in treating cancer patients.
Inhibition of Metastasis
Chemotherapy is an important therapeutic modality for managing 
a variety of cancers. However, chemotherapy frequently fails to achieve 
a satisfactory therapeutic outcome such as complete remission or 
prevention of distant metastasis with no major chemotherapy-related 
side effects [23]. Cancer metastasis, in particular, is a major medical 
problem in treating cancer.
The potential application of PL as an immunotherapeutic agent, 
especially for cancer metastasis, has been actively investigated. PL alone 
significantly prolonged the survival rate of B16F10 cell-implanted 
mice, inhibited tumor growth in NCI-H [23] cell-implanted nude 
Author, year Direct anticancer effect Observation Mechanism
Song et al. [56] 
Inhibits tumor growth and 
invasion
(colon cancer cells)
-PL significantly inhibited cell proliferation and decreased 
β-catenin expression in SW480 cells.
-Expression of cyclin D1, TCF/LEF, MMP-9 were also significantly 
reduced by PL treatment.
Inhibition of Wnt/β-catenin signaling 
Li et al. [17] Antiproliferative effect(colon cancer cells)
-PL inhibited HT-29 cell proliferation
-Decreased expression of Reg IV, and EGFR mRNA
- Decreased plasma Reg IV, EGFR, Akt concentration
Down-regulating Reg IV and EGFR  may lead to 
disruption of the Reg IV/EGFR/Akt signaling pathway
Lu et al. [57]
Inhibits tumor growth
(breast and bladder cancer 
cells)
-Hispolon from PL inhibited cancer cell growth
- p21WAF1, a cyclin-dependent
kinase inhibitor, was elevated in hispolon-treated cells
- MDM2, a negative regulator of p21WAF1, was degraded after 
hispolon treatment.
-Activated ERK1/2 was recruited to MDM2 leading to MDM2 
degradation
Hispolon from PL ubiquitinates and downregulates 
MDM2 via MDM2-recruited activated ERK1/2 and 
upregulates p21WAF1
Guo et al. [31] Cancer growth arrest(lung cancer cells)
-PL induces cell-cycle arrest at a low concentration.
-Associated with decrease of CDK 2, 4 and 6
PL suppresses the activation of CDK  unable to 
form complexes with cyclin D,E, or A  maintains 
phospho-Rb  blockage of cell-cycle progression 
Sliva et al. [36]
Suppressed growth and 
invasive behavior
(breast cancer cells)
-PL inhibits proliferation and colony formation,
-Growth inhibition is mediated by cell cycle arrest at S phase 
through upregulation of p27Kip1 
- Suppression of invasion by inhibition of cell adhesion, cell 
migration and cell invasion through suppression of uPA secretion 
Inhibition of serine-threonine
kinase AKT signaling, upregulation of p27Kip1, and 
suppression of uPA
TCF/LEF, T-cell factor/lymphocyte enhancer binding factor; MMP, matrix metalloprotease; EGFR, epidermal growth factor receptor; ERK1/2, extracellular signal-regulated 
kinase1/2; CDK, cyclin-dependent kinase; uPA urokinase-plasminogen activator
Table 1: Direct anticancer effects of PL and proposed molecular mechanisms.
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mice, and reduced the frequency of pulmonary metastasis of B16F10 
cell melanomas compared to adriamycin, which significantly inhibited 
tumor growth, but only slightly inhibited metastasis. PL was not directly 
toxic to cancer cells, suggesting its mechanism is through stimulation 
of the immune response [24]. In another study [25], PL markedly 
inhibited melanoma cell metastasis in mice by a direct inhibitory effect 
on the adhesion to and invasion through the extracellular matrix of 
cancer cells. In addition, PL increased macrophage NO production. 
Lee et al. [26] demonstrated that PL might inhibit metastasis at least 
in part through the regulation of urokinase type plasminogen activator 
(uPA) associated with tumor cell-induced platelet aggregation. 
Although PL showed no cytotoxicity against invasive melanoma cells 
(B16BL6 cells), PL inhibited platelet aggregation induced by B16BL6 
cells. It also disrupted the adhesion to gelatin and invasion of B16BL6 
cells in a concentration-dependent manner. PL dose-dependently 
inhibited pulmonary metastatic colonies up to 55.5% in C57BL/6 mice 
intravenously injected with B16BL6 cells compared with untreated 
controls. In addition, PL resulted in concentration-dependent down 
regulation of the expression of uPA, a key protein in invasion and 
metastasis of tumor cells. 
Recurrence, especially of distant liver metastasis, is a major 
problem in treating pancreatic cancer following margin-negative 
pancreatectomy. Recently, FOLFIRINOX successfully demonstrated 
excellent survival in patients with metastatic pancreatic cancer. 
However, the significant side effects could limit its general application 
in clinical practice [3,27,28]. Therefore, effective anti-metastatic 
therapeutic agents need to be further investigated. PL may be a potential 
candidate as a natural nontoxic agent.
Induction of Apoptosis
Apoptosis is fundamental process essential for cancer cell death. 
Deregulation of apoptosis is related to cancer progression. Caspase 3 
is important in the propagation of apoptotic signaling. In the caspase 
cascade, a loss of mitochondrial transmembrane potential results 
in an increase in the permeability of the mitochondria membrane. 
Cytochrome C is released to the cytosol, leading to apoptosis [29]. 
The first description of PL-mediated apoptosis in colon cancer 
cells was reported in 200413. In this study, polysaccharide from PL 
(Mesimaw) had an antiproliferative effect on SW480 human colon 
cancer cells. The effect was mediated through the induction of apoptosis 
and G2/M cell cycle arrest, and was associated with a decrease in Bcl-2, 
an increase in the release of cytochrome C, and a reduction in cyclin 
B1 expression. PL was also found to augment doxorubicin (Dox)-
induced apoptosis in prostate cancer (LNCaP cells) [30]. PL and Dox 
do not induce apoptosis, but a combination of low doses of PL and Dox 
resulted in a synergistic effect on apoptosis induction. In this process, 
caspases 8, 3, BID were activated. JNK is also activated in response to PL 
or combination treatment. The antitumor effect derived from apoptosis 
induction was also demonstrated in mouse and human lung cancer 
cells [31]. In response to a high-dose PL treatment, lung cancer cells 
underwent apoptosis accompanied by the activation of caspase 3 and 
cytochrome C release. The addition of a caspase inhibitor (Z-VADfmk) 
completely suppressed apoptotic processes meditated by high-dose PL 
in lung cancer cells. An in vivo study showed the antitumor property 
of PL is to induce apoptosis in athymic nude mice model inoculated 
with prostate cancer DU145 or PC3 cells [32]. Injection of PL caused 
dramatic tumor regression by triggering apoptotic processes, as 
demonstrated by histopathology, immunohistochemistry (TUNEL 
and caspase3), and Annexin V assays. These studies indicated that the 
upregulation of apoptosis or resensitizing cells to apoptotic stimulation 
is a promising potential cancer therapy. 
Inhibition of Angiogenesis
Angiogenesis refers to the formation of new blood capillaries 
from existing ones. This complex process involves degradation of 
the extracellular matrix, migration and proliferation of endothelial 
cells, tube formation and sprouting of new capillary branches 
[33]. Angiogenesis is necessary for both cancer growth and tumor 
transplantation and metastasis. Therefore, inhibition of angiogenesis 
can be a potential strategy to suppress tumor growth and metastases. 
The anti-angiogenic activity of PL was measured using a 
Chorioallantoic Membrane (CAM) assay, which is used for detecting in 
vivo angiogenesis. PL showed potent, dose-dependent anti-angiogenic 
activity in the CAM assay [34]. However, the mechanism by which PL 
induces anti-angiogenesis was not fully addressed. A recent study [35] 
found that PLME (the methanol extract of PL) had anti-angiogenic 
effects through inhibition of human umbilical vein endothelial 
cell proliferation, migration, and assembly into capillary-like 
structures. These effects were mediated by the inhibition of VEGFR-2 
phosphorylation. In addition, when human aortic endothelial cells 
were treated with PL or with conditioned media from the breast cancer 
cell line MDA-MB-231treated with PL (0–0.5 mg/ml), PL significantly 
suppressed capillary morphogenesis of human aortic endothelial cells 
in a dose-dependent manner, compared with conditioned media from 
cells not treated with PL. This anti-angiogenic effect of PL was reported 
to be due to suppression of AKT activity, which inhibits secretion of 
VEGF from breast cancer cells [36]. These results demonstrate that PL 
might be a novel inhibitor of angiogenesis, suggesting that PL could be 
a new alternative therapeutic agent for angiogenesis-mediated tumor 
treatment.
Synergetic Effects with Chemotherapeutic Agents
A potentially applicable clinical strategy for PL might be using PL as 
an adjuvant in combination with cytotoxic anticancer agents. However, 
clinical studies on the feasibility and rationale of PL as a combination 
anti-cancer treatment are lacking, with only a single in vitro study 
available. Collins et al. [30] explored the potential combination 
treatment of Dox and PL against prostate cancer based on studies 
suggesting that Dox can synergize with TRAIL to elicit cytotoxicity in 
various tumors [37-40]. PL also inhibited tumor growth. This study 
showed that PL might act by interfering with the antiapoptotic factor 
c-FLIP to enhance sensitization of the Dox-mediated apoptotic signal 
pathway. The results suggest that a combination of PL with a cytotoxic 
agent could have synergistic anticancer effects in patients. Similarly, 
Guo et al. [31] demonstrated a synergistic effect of PL in combination 
with Dox in lung cancer cells. Cells were treated with PL (0.5 mg/
mL), a low dose of Dox (0.5 mg/mL) alone, or a combination of PL 
and Dox. Treatment with PL or Dox, or the combination of PL and 
Dox failed to induce apoptosis in normal lung epithelial cells. Lung 
cancer cells (LKR or H5800 cells) were also insensitive to either single 
treatment. However, the combination of the two reagents increased 
the percentage of DNA fragmentation in cancer cells (more than20%). 
This indicated the occurrence of apoptosis, suggesting that PL and Dox 
have a synergistic effect on the induction of apoptosis in lung cancer 
cells. Another potential use of the genus Phellinus as an adjuvant 
combination therapy with conventional anticancer treatments was 
demonstrated by Phellinus igniarius, in the same family as P. linteus. 
P. igniarius ethanol extract at 25 or 50 ug/mL in combination with 
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oxaliplatin or 5-ﬂuorouracil synergistically inhibited the proliferation 
of human hepatocellular carcinoma cells (SK-Hep-1) [41]. 
Antitumor Activity of Mushroom Derivatives on 
Pancreatic Cancer
Till now, no study has been performed about the anticancer effect 
of PL, however, there are a few experimental data supporting potential 
anti-tumor activity of mushroom against pancreatic cancer. Simply, 
although it was not related to PL, another mushroom extract from 
Cyathusstriatus was shown to inhibit the viability of human pancreatic 
adenocarcinoma cells; HPAF-II and PL 45. It was noted that growth 
inhibition could be achieved even in low concentration with short 
exposure period [42]. The growth of pancreatic cancer BXPC3 cells also 
were found to markedly be inhibited by MMH01, a compound isolated 
from Antrodiacinnamomea. In BxPC3 cells, MMH01 treatment 
resulted in ballooning, a unique morphologic changes known as an 
early apoptosis. This morphologic changes, but no DNA fragmentation 
suggested the mode of cell death induced by MMH01 in pancreatic 
cacnerBxPC3 might be apoptosis-associated events of necrosis [43].
Recently, the underlying potential mechanisms were actively 
investigated. Yu et al. [44] demonstrated that antroquinonol, a 
ubiquinone derivative isolated from a camphor tree mushroom, 
Antrodiacamphorata, induced a concentration-dependent inhibition 
of cell proliferation in pancreatic cancer PANC-1 and AsPC-1 cells. 
This anticancer activity in human pancreatic cancers was found to be 
through an inhibitory effect on PI3-kinase/Akt/mTOR pathways, which 
results in down-regulation of cell cycle regulators. It was also noted that 
antroquinonol induces the cross talk between apoptosis, autophagic 
cell death and accelerated senescence by up-regulation of p21WAF/Cip1 
and K-ras. With regarding cyclin-dependent kinase inhibitor, p21WAF/
Cip1, Rosendahl et al. [45] also found that Polysaccharide K (PSK) 
increases p21WAF/Cip1 and promotes apoptosis in pancreatic cancer cells. 
They showed the antiproliferative action of PSK in BxPC-3, PANC-1, 
MIAPaCa-2, and AsPC-1 was associated with up-regulated cell cycle 
regulatory p21WAF/Cip1 and pro-apoptotic protein Bax levels, resulting in 
cell cycle arrest and induction of apoptosis. 
Another study evaluated the antitumor mechanism of protein 
pound polysaccharide under hypoxia because pancreatic cancer 
is known to be related with high level of hypoxia. Based on the 
previous observation that HIF-1α and Hedgehog (Hh) signal pathway 
independently regulate the proliferation and invasiveness under 
the hypoxia [46], Onish et al [47], demonstrated PSK decreased 
proliferation in PDAC cells under hypoxia, and it definitely inhibited 
invasiveness of human pancreatic ductal cell lines (ASPC-1, and SUIT-
2). PSK was also noted to decrease the expression of HIF-1α and 
hedgehog (Hh) signaling-related molecules under hypoxia, in turn, 
this inhibition of HIF-1α and Hh signaling reduced proliferation and 
invasiveness in PDAC cells under hypoxic condition.
PSK from Basidiomycete Coriolusversicolr also shown to inhibit 
pancreatic cell line (NOR-P1) by down-regulation of TGF-β1 and 
MMPs. TGF-β1, the predominant from in human and the most widely 
studied isoform of TGF-βs, is potent invasion-promoting factors. 
MMPs are implicated in tumor cell invasiveness. Zhang et al. [48] 
observed that PSK significantly decreased the invasiveness of NOR-P1 
cancer cells in Martrigel-coated filters, and decreased invasion was 
associated with inhibition of TGF- β1, and MMPs. 
PSK-induced indirect antitumor activity by augmenting immune 
system was investigated in early 1990. Noguchi et al. [49] found that 
PSK directly augments the proliferation and cytotoxicity of tumor-
infiltrating lymphocytes (TILs). TILs defined as lymphocytes found 
within the tumor tissue and are known to develop as manifestations of 
the recognition and defense against malignant cells by the host immune 
system. Therefore, the potential role of TILs has been demonstrated 
by the prognosis of TILs in pancreatic cancers [50-52]. They observed 
that DNA synthesis of TILs was increased by incubation with PSK, 
which was similar to serum level with oral administration of PSK in 
cancer patients. Although PSK did not affect the cytotoxic activity 
of TILs against autologous tumor cells in the 4h 51Cr release assay, 
PSK induced high lysability in the 16-h 51Cr release assay. The DNA 
synthesis of tumor cells was more suppressed by the mixed-tumor cell 
culture supernatants of TILs cultured with PSK, compared to that of 
TILs cultured without PSK, suggesting that PSK induced killing activity 
of TILs by induction of cytotoxic cytokines.
In early 2000, Zhang et al. [53] also demonstrated PSK-mediated 
NF-κB inhibition enhanced docetaxel-induced apoptosis in human 
pancreatic cancer cells. Although PSK alone did not show an effect 
on the viability of human pancreatic NOR-P1 cancer cells, it dose-
dependently enhanced docetaxel-induced apoptosis, suggesting 
combination of PSK with a low dose of docetaxel may be a new 
therapeutic strategy to treat pancreatic cancer patients. However, 
there is no clinical study evaluating the potential role of mushroom 
derivatives in clinical practice of treating pancreatic cancer. In 1987, 
only two cases of unresectable pancreatic cancer responding to 
combined chemotherapy with cisplatin, PSK, and UFT were reported 
[54].
Oncologic Impact of Polysaccharides from Phellinus 
linteus (Aclang®) in with Postoperative Adjuvant 
Chemotherapy in Pancreatic Cancer after Surgical 
Resection: A retrospective pilot study
In Korea, commercialized polysaccharides from P. linteus (Aclang, 
Kwang Dong Pharmaceutical Co., Ltd, Korea) are available for clinical 
use and are covered by medical insurance during postoperative 
chemotherapy for gastrointestinal malignancy. In this study, we 
retrospectively investigated the potential oncologic impact of Aclang 
with postoperative adjuvant chemotherapy in pancreatic cancer with 
surgical resection.
A total of 103 patients underwent surgical resection for ductal 
adenocarcinoma of the pancreas at Severance Hospital, Seoul, Korea, 
from January 2006 through December 2010. We retrospectively analyzed 
the medical records of the 53 patients who received postoperative 
adjuvant chemotherapy without neoadjuvant chemotherapy. In a subset 
of these patients, Aclang was given concomitantly with postoperative 
chemotherapy. Two chemotherapy regimens were used: gemcitabine-
based therapy and 5-FU-based therapy. Gemcitabine was administered 
at 1000 mg/m2 as a 60-minute intravenous infusion on days 1, 8, and 
15 over a four-week cycle. Cisplatin (70 mg/m2) was sometimes added 
to the gemcitabine infusion on day 1. For 5-FU based chemotherapy, 
5-FU was administered intravenously at 1000 mg/m2 on days 1, 2, and 
3 of the cycle, and carboplatin (350 mg/m2) was added on day 2 of the 
cycle. Aclang (1100 mg, 550 mg/capsule x 2) was administered orally 
3 times per day for 2–4 months during postoperative chemotherapy. 
We divided patients into two groups according to Aclang use. The 
clinicopathological features of the two groups were compared using 
Mann-Whitney U-tests for continuous data, and are presented as 
median values (ranges). Chi-squared tests or Fisher’s exact tests for 
categorical variables were used as appropriate. Disease-free and overall 
Page 5 of 8
Citation: Kang CM, Han DH, Hwang HK, Choi SH, Lee WJ (2013) Anticancer Effect of Phellinus linteus; Potential Clinical Application in Treating 
Pancreatic Ductal Adenocarcinoma. J Carcinogene Mutagene S9: 001. doi:10.4172/2157-2518.S9-001
J Carcinogene Mutagene                                                                                                                    ISSN:2157-2518 JCM, an open access journal journal Pancreatic Ductal Adenocarcinoma
survival curves were obtained using the Kaplan-Meier method, and 
differences in survival between groups were compared using a log-rank 
test. Statistical analysis was conducted using SPSS software version 18 
for Windows (SPSS Inc. Chicago, IL, USA). P <0.05 was considered to 
be statistically significant.
Clinicopathological analysis of postoperative 
polysaccharide Phellinus linteus (Aclang)
From January 2006 through December 2010, 103 patients 
underwent pancreatectomy for pancreatic ductal adenocarcinoma. A 
total of 53 underwent postoperative adjuvant chemotherapy without 
neoadjuvant chemoradiation therapy and were included in this study. 
Most patients (39, 73.6%) received gemcitabine-based postoperative 
adjuvant chemotherapy, and the remainder received 5FU-based 
postoperative adjuvant chemotherapy. Aclang was given to 35 patients 
during postoperative chemotherapy treatment. Median disease-free 
survival was 6.9 months (95% Confidence Interval [CI]; 4.6-9.2), and 
median overall disease-specific survival was 42.3 months (95% CI; 
22.8-61.8).Our comparative analysis showed no clinicopathological 
differences between groups (Table 2). Perioperative and pathological 
characteristics including T-stage, N-stage, lymphovascular invasion, 
perineural invasion, tumor grade, and margin status were similar 
between the groups.
Oncologic impact of Aclang with postoperative 
chemotherapy in pancreatic cancer after surgical 
resection.
The anticancer effects of polysaccharides from Aclang were 
estimated using survival outcomes for each group. Clinicopathological 
differences were not seen between groups. However, disease-free 
survival was significantly different for postoperative use of Aclang with 
adjuvant chemotherapy. While median disease-free survival was 2.8 
months (95% confidence interval; 0.143-5.457) in patients that did not 
receive Aclang®, median disease-free survival was 11.0 months (95% 
CI; 5.329-16.738, P = 0.017) in patients treated with Aclang. However, 
overall disease-specific survival was not significantly different between 
groups (Figure 2). 
Summary comments
To the best of our knowledge, this study is the first clinical report 
suggesting that PL could potentially be used to treat pancreatic 
cancer.  Despite that postoperative use of Aclang with postoperative 
adjuvant chemotherapy was observed to significantly delay tumor 
recurrence, overall disease-specific survival was similar. Moreover, 
median disease-free survival (DFS) (2.8 months in control group vs. 
11.0 months in à Aclang group) appears to be too short and does not 
appear to be beneficial oncologic impact when comparing to DFS of 
the 6.9 months in the surgery-alone group vs.13.4 months in patients 
with surgery followed by the administration of gemcitabine on 
CONKO-001 trial [55]. Especially, in treating patients with recurrence, 
most of patients received different chemotherapeutic agents including 
DDP, oxaliplatinc, TS-1, Xeloda, and combined radiotherapy. In 
some cases of local liver metastasis, radiofrequency ablations or 
transarterial chemoembolization with systemic chemotherapy were 
performed. Various chemotherapeutic agents were heterogeneously 
applied according to patients’ general condition and preference of the 
oncologist. Therefore, it cannot be emphasized that PL has definite 
oncologic role in treating pancreatic cancer because this study is 
Control group 
(n = 18)
Aclang group
(n = 35) P-value
Age (years) 63.2 ± 9.5 62.5 ± 9.0 0.749
Sex Female/Male 8/10 14/21 0.756
Biliary decompression No/Yes 12/6 20/15 0.502
Tumor Location Head/ Body+Tail 11/7 23/12 0.590
Resectability1 PR/BR/LA 14/4/0 23/11/1 0.602
Operation PD/ DPS/TP 10(8)*/7/1 23(21)*/12/0 0.392
Vascular resection2 No/Yes 16/1 29/6 0.576
Blood loss (ml) 709.4 ± 556.9 660.2 ± 423.1 0.667
Transfusion No/ Yes 12/5 25/10 0.726
Operation time (min) No/ Yes 423.3 ± 192.2 426.0 ± 171.9 0.843
Tumor Size (cm) 2.7 ± 1.8 2.9 ± 1.3 0.585
T-stage T1/T2/T3/T4 0/0/17/0 1/1/31/2 0.510
N-stage N0/N1 7/10 13/22 0.964
PNI No/ Yes 6/11 11/23 0.781
LVI No/ Yes 12/5 19/15 0.655
Tumor Grade Well 6 5 0.466
Moderate 11 26
Poor 1 3
Undifferentiated 0 1
R0 resection R0/R1/R2 15/2/0 29/3/3 0.590
Postoperative chemotherapy GEM-based/ 5FU-based 11/7 28/7 0.198
LOH (days) 22.6 ± 12.1 19.9 ± 9.7 0.553
POPF No/ Yes 15/2 34/1 0.915
Mortality No/ Yes 17/0 35/0 NA
12010 NCCN guidelines, PR=potentially resectable, BR=borderline resectable, LA=locally advanced
2Portal vein wedge resection (1) in the control group vs. portal vein segmental resection, (2) wedge resection, or (3) in the Aclang group. * ; indicates pylorus-preserving 
procedure. PNI; perineural invasion, LVI; lymphovascular invasion, LOH; length of hospital stay, POPF; postoperative pancreatic fistula
Table 2: Clinicopathological features of patients in Aclang and control groups.
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a retrospective and pilot study based on small patients’ number. 
However, as long as this pilot study showed the statistical difference in 
oncologic outcome was observed, between two groups, and there are 
several published scientific back ground for PL and some mushroom 
derivatives from mushroom in treating pancreatic cancer, we cannot 
overlook this observation. It should be re-evaluated in prospective 
randomized control study in near future. We cannot be sure that 
Aclang had anticancer effects in pancreatic cancer. However, our pilot 
study provides clinical clues for performing future randomized control 
studies on the potential of PL for treating resected pancreatic cancer.
 
 
 
Figure 2: Oncologic outcomes according to use of polysaccharide Phellinus linteus (Aclang®) 
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Figure 2: Oncologic outcomes according to use of polysaccharide Phellinus linteus (Aclang®)
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The anticancer effect of Phellinus linteus (PL) has been studied, but use of PL for pancreatic cancer seems to be an unexplored area. The pilot study presented here 
encurages further investigation on PL for pancreatic cancer treatment.
Figure 3: Unveiled potential oncologic role of Phellinus linteus in pancreatic cancer treatment.
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Conclusions
Given the poor survival rates of patients with pancreatic cancer, 
a critical need exists to develop alternative treatments to improve 
oncologic outcomes of pancreatic cancer. In spite of accumulating 
evidence for the antitumor effect of PL and mushroom derivatives, until 
now, no studies have examined the potential anticancer mechanism of 
PL in pancreatic cancer. Clinical research on the potential of PL for 
pancreatic cancer treatment is sparse. In addition, no sound evidence 
does exists on the proper dosage and treatment period for PL as an 
adjuvant agent in managing pancreatic cancer. Therefore, future studies 
need to validate the oncologic impact of PL on resected pancreatic 
cancer. In addition, the exact mechanisms of action of PL in pancreatic 
cancer pathogenesis should be investigated (Figure 3).
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